The Evidence Based Rheumatology Podcast

Michael Putman

An evidence based medicine podcast for the field of rheumatology

  • 13 minutes 6 seconds
    E130: Telitacicept for SLE

    Surprisingly (unbelievably?) impressive RCT evaluating the Blys/APRIL inhibitor "telitacicept" for patients with SLE (mixed SLE and SLE-LN). Very curious to see where the FDA goes with this one. 

     

    Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2414719

    22 December 2025, 11:07 pm
  • 15 minutes 17 seconds
    E129: Long Term Routine Laboratory Monitoring in RA

    Ever wonder how often you really need to check "monitoring" labs? If so then this is the podcast for you! Bryant England mentioned this during his excellent Year in Review session at ACR Convergence 2025. I've been meaning to cover it and finally got around to doing so. Have a listen and share with friends!

     

    Paper: https://pubmed.ncbi.nlm.nih.gov/40854212/

    4 December 2025, 1:02 pm
  • 19 minutes 3 seconds
    E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD)

    Covering a very interesting study this week, which investiaged the PDE4B inhibitor nerandomilast for patients with progressive pulmonary fibrosis (specifically including 325 patients with autoimmune ILD). Would have been yet another ho hum trial if not for the big reveal... have a listen to find out!

    Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2503643

     

    12 November 2025, 6:07 pm
  • 21 minutes 46 seconds
    E127: TNFs and All That CHF

    Another episode looking into safety this week! Tackling that pesky issue of TNFs and CHF. Be sure to subscribe to my newsletter and check out the papers below! 

     

    Newsletter: https://sprw.io/stt-ee87b4

    ATTACH: https://pubmed.ncbi.nlm.nih.gov/12796126/

    RENEWAL: https://www.ahajournals.org/doi/10.1161/01.cir.0000124490.27666.b2

    Observational Studies: https://pubmed.ncbi.nlm.nih.gov/23155221/

     

    22 September 2025, 6:22 pm
  • 14 minutes 34 seconds
    E126: Risk Signals, JAKs, and SELECTIVE-ity

    Covering an interesting but ultimately disappointing post hoc study of multiple upadacitinib trials in RA. Initially some hope for clarity in the "Do JAKs cause all the badness?" questions, but ultimately landing me about where I have been since ORAL-SURVEILLANCE was published

    Paper: https://www.sciencedirect.com/science/article/pii/S0003496724423091

     

    8 September 2025, 5:45 pm
  • 17 minutes 52 seconds
    E125: Adrenal Insufficiency after Stopping Prednisone

    Interesting read this week - I cover a nifty little paper that presented data about adrenal insufficiency after stopping prednisolone, published in JAMA Open in March 2025.  

     

    Open Access Journal Here: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831668

    29 June 2025, 8:52 pm
  • 14 minutes 18 seconds
    e124: MTX vs Pred for Pulmonary Sarcoidosis: PREDMETH Study

    Interesting NEJM trial this week comparing methotrexate to prednisone for pulmonary sarcoidosis.

    Paper available here: https://www.nejm.org/doi/full/10.1056/NEJMoa2501443 

    12 June 2025, 4:27 pm
  • 18 minutes 13 seconds
    E123: Upadacitinib for Giant Cell Arteritis: SELECT-GCA

    Podcast this week about the recently published SELECT-GCA study, which evaluated the use of the janus kinase inhibitor upadacitinib (Rinvoq) for patients with new and relapsing GCA. Successful trial and an interesting topic. Paper itself here: https://www.nejm.org/doi/full/10.1056/NEJMoa2413449

    30 April 2025, 3:33 pm
  • 11 minutes 18 seconds
    E122: Guidelines for Maybe Diagnosing HLH

    This week I cover another of my newsletters, though I mostly use it as a skeleton to riff on a common (and challenging) issue for rheumatology consultants; diagnosing HLH. Check out the guidelines themselves here and have a listen to the podcast! 

     

    https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00273-4/fulltext

    17 April 2025, 5:26 pm
  • 18 minutes 14 seconds
    E121: Obinutuzumab in SLE-LN

    Another day, another b cell podcast. Seems to be all the rage! This week I discuss the recently published NEJM trial of the anti CD20 agent obinutuzumab in lupus nephritis. Worth a read and listen, paper can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa2410965

    2 April 2025, 5:07 pm
  • 24 minutes 33 seconds
    E120: Real Life Use of PEXIVAS-Low

    What do you do when observational data and RCTs conflict? This week I'm covering the "real world PEXIVAS" study that was done by the French Vasculitis Study Group. Great read, interesting issues, have a listen and be sure to share with friends! 

    6 March 2025, 5:00 pm
  • More Episodes? Get the App